FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Hexarelin

Examorelin / HEX

Growth Hormone Secretagogues

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

作用機序

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection. GH response attenuates after 4-8 weeks (tachyphylaxis). Often cycled 8 weeks on, 4 weeks off.

研究ノート

Clinical Research Status

Hexarelin has been studied in multiple Phase 1/2 clinical trials for growth hormone deficiency, cardiac function, and aging-related decline, but has not progressed to regulatory approval. Italian cardiovascular research groups have published extensively on its direct cardiac effects independent of GH release. It remains available primarily as a research chemical, with clinical interest continuing in growth hormone secretagogue pharmacology and cardioprotection.

Key Published Findings

Studies demonstrate hexarelin produces the largest GH release among GHRPs, with peak GH levels of 30-50 ng/mL in healthy subjects after a single subcutaneous dose. Cardiovascular research shows hexarelin directly binds cardiac receptors (CD36), reducing cardiac fibrosis and improving ventricular function independent of GH/IGF-1 signaling. However, hexarelin shows significant tachyphylaxis with continuous use, with GH response diminishing substantially after 4-8 weeks of daily administration.

Safety Profile

Short-term studies show hexarelin is well-tolerated with common effects including transient hunger increase, flushing, and mild water retention consistent with GH elevation. The pronounced cortisol and prolactin co-stimulation distinguishes hexarelin from more selective GHRPs like ipamorelin. Tachyphylaxis (reduced response over time) limits its practical utility for sustained GH elevation, though pulsatile or intermittent protocols may partially mitigate this.

Comparison to Related Compounds

Hexarelin produces stronger GH release than GHRP-6 or GHRP-2 but with greater cortisol and prolactin stimulation, making it less selective. Compared to ipamorelin, which is highly GH-specific, hexarelin's broader receptor activation produces additional cardiovascular effects but more side effects. Unlike GHRH analogs (CJC-1295, sermorelin), hexarelin works through the ghrelin receptor pathway and can synergize with GHRH for amplified GH release.

Community Observations

Researchers note that hexarelin's rapid tachyphylaxis makes it poorly suited for continuous long-term GH elevation protocols. Its unique cardioprotective properties have generated interest separate from GH-releasing applications, particularly for post-myocardial infarction recovery research. Some protocols use hexarelin in short cycles (2-4 weeks) or intermittently to maximize GH response before tachyphylaxis develops.

半減期

~1 hour

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 18 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

ExamorelinHEX

よくある質問

Hexarelinとは何ですか?

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

Hexarelinはどのように作用しますか?

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

Hexarelinの米国での規制状況は?

Research chemical (not FDA-approved)

Hexarelinの半減期は?

~1 hour

Hexarelinの別名は?

Examorelin, HEX

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む